About Allarity Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://allarity.com/
Frequently Asked Questions
What is the 52-week range for ALLR?
The 52-week high is $1.8395 and the 52-week low is $0.769.
What is the P/E ratio for ALLR?
The P/E ratio data is currently unavailable.
What is the dividend yield for ALLR?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -152.77%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.76.
Analyst Recommendation Trends
Wall Street analyst consensus for ALLR over the last few months:
Latest ALLR News
Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development
- Recently awarded patents have solidified Allarity’s strategy to leverage DRP to ensure the commercial exclusivity of stenoparib TARPON SPRINGS, Fla., September 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today provided an update on recent advances in its proprietary Drug Response Predictor (DRP®) technology,
Allarity Therapeutics Highlights DRP Technology, Patent And Lab Advances To Support Stenoparib Development And Partnerships
Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New proteomics and cell line capabilities will broaden Allarity’s research capabilities to enable external partnerships TARPON SPRINGS, Fla., September 28, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today announced that
Allarity Therapeutics Expands Capabilities Of Its In-House Medical Laboratory To Include Proteomics And Cell Line Research
- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib- New proteomics and cell line capabilities will broaden Allarity’s research capabilities to enable external
Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
Lobo Technologies shares surged 32% premarket after a narrower H1 loss and higher sales; several small caps rallied while others fell sharply.
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $10.25 to $11.
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
TARPON SPRINGS, Fla., September 15, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the Japan Patent Office (JPO) has granted a key patent covering Allarity’s proprietary stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic. The newly granted patent, Japanese Patent No. 7917283, p
Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement
TARPON SPRINGS, Fla., September 11, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor using its proprietary DRP® technology, announced that Allarity Acquisition Corp., a newly formed special purpose acquisition company (SPAC), has publicly filed a Registration Statement on Form S-1 (the “Registration Statement”) with the U.S. Securitie
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-01-28 | Jensen Thomas | +200,000 | - | - |
| 2026-01-28 | McLaughlin Gerald W. | +45,000 | - | - |
| 2026-01-28 | Ervin Jeffrey S | +150,000 | - | - |
| 2026-01-07 | Hoeiland Jesper | +25,000 | - | - |
| 2026-01-07 | Graff Jeremy R. | +133,333 | - | - |